The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 4, 2022. Its latest SEC filing is a SC 13G/A from Feb 10, 2023.
10-Q for Q3 FY2022, filed Nov 4, 2022
The sections below describe the company as of the FY2021 annual report.
Sold Rhopressa and Rocklatan glaucoma eye drops to pharmaceutical distributors and developed ophthalmic therapies for glaucoma, dry eye and retinal diseases.
10-K for FY2021, filed Feb 25, 2022
Wholesalers bought Rhopressa and Rocklatan; the company invoiced them by delivery, with payment under standard credit terms. License agreements brought upfront fees, development, regulatory and sales milestones, drug-supply charges, and royalties on licensed-product sales.
10-K for FY2021, filed Feb 25, 2022
10-K for FY2021, filed Feb 25, 2022
FY2021 revenue by product or service ↗$194.1M
10-K for FY2021, filed Feb 25, 2022
$194.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenues, net
Sold outright
10-K for FY2021, filed Feb 25, 2022 |
58%
FY2018: 100%
|
Product revenues, net, FY2021
$112.1M Sources
|
Sold outright |
|
Licensing revenues
Licensed
10-K for FY2021, filed Feb 25, 2022 |
42% |
Licensing revenues, FY2021
$82M Sources
|
Licensed |
U.S. wholesalers bought the glaucoma products and resold them mainly to retail pharmacies. Santen held rights to develop and commercialize products in Japan, East Asia and other licensed markets.
10-K for FY2021, filed Feb 25, 2022Aerie’s customers include a limited number of national and select regional wholesalers (the “distributors”). These distributors…View ↗
In October 2020, Aerie Ireland Limited entered into the First Santen Agreement with Santen, a global ophthalmology company, whereby Aerie…View ↗
We have partnered and have collaboration agreements in place with Santen Pharmaceuticals Co., Ltd. (“Santen Pharmaceuticals”) and Santen SA…View ↗
December 2021 to develop and commercialize Rhopressa® and Rocklatan® in Europe, China, India, the Middle East, CIS, Africa, parts of Latin…View ↗
10-K for FY2021, filed Feb 25, 2022
No. It lost $74.8M in FY2021.
10-K for FY2021, filed Feb 25, 2022
−$46.4MView ↗
10-K for FY2021, filed Feb 25, 2022
−$74.8MView ↗
10-K for FY2021, filed Feb 25, 2022
−$102.4MView ↗
10-Q for Q3 FY2022, filed Nov 4, 2022
−$26.8MView ↗
8-K, filed Nov 21, 2022
At the Effective Time, and by virtue of the Merger, each share of common stock, par value $0.001 per share, of the Company (the “Shares”)…View ↗
International commercialization
The company had planned to commercialize the products itself in Europe and seek a Japan partner; it later entered Santen agreements to develop and commercialize them across Europe, Japan, East Asia and other regions.
10-K for FY2018, filed Mar 1, 2019 10-K for FY2021, filed Feb 25, 2022Our strategy also includes developing our business outside the United States, including obtaining regulatory approval in Europe and Japan…View ↗
Rocklatan's U.S. status
Rocklatan moved from an advanced-stage U.S. product candidate to an FDA-approved glaucoma product sold alongside Rhopressa.
10-K for FY2018, filed Mar 1, 2019 10-K for FY2021, filed Feb 25, 2022We are an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the…View ↗
Our strategy is to grow the market share of our U.S. Food and Drug Administration (“FDA”) approved glaucoma franchise products, Rhopressa®…View ↗
Competes with Bausch Health, Novartis International, Sandoz, Alcon, AbbVie, Teva Pharmaceutical Industries, Sun, Santen, and Nicox
10-K for FY2021, filed Feb 25, 2022The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary…View ↗
Loading...
